Wojciech Jurczak

30PUBLICATIONS
138CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedGene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 05, 2026
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

|Jul 16, 2026
First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.

|Jul 01, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

|Dec 29, 2025
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Jeremy S Abramson, David J Straus, Nancy L Bartlett

|Dec 09, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz

|Dec 07, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki

Pageof 5

Frequent Collaborators

9 joint publications

Paolo Ghia

8 joint publications

Jennifer A Woyach

4 joint publications

Jennifer R Brown

4 joint publications

Constantine S Tam